article thumbnail

Taskforce on Nature-Related Financial Disclosures Framework: Overview of First Beta Release

Harvard Corporate Governance

In March, the Taskforce on Nature-related Financial Disclosures released the first beta version (v0.1) The first beta release marks the beginning of an 18-month consultation and development process to improve the Framework’s relevance, usability and effectiveness. Roe (discussed on the Forum here ).

Beta 212
article thumbnail

TNFD Recommendations for Nature Related Disclosures

Harvard Corporate Governance

Fortt, Latham & Watkins LLP, on Saturday, October 21, 2023 Editor's Note: Austin J. These recommendations were the result of a two-year engagement process, featuring several beta versions to receive and process commentary from a range of stakeholders. Posted by Austin J. Pierce, Betty M. Huber, and Sarah E. Huber and Sarah E.

Beta 213
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Tesla in November 2023 : Story twists and turns, with value consequences!

Musings on Markets

As the price dropped below $200 today (October 30,2023), I decided that it was time for me to revisit and revalue the company, taking into account the news, financial and other, that has come out since my last valuation in January 2023, and to understand the dueling stories that are emerging about the company. billion on revenues of $95.9

Start-ups 126
article thumbnail

Investment Giant BlackRock's Strong Finish To 2023: Dividend Boost, Accretive Acquisition & More

Benzinga

billion a year ago, led by market beta on average AUM, positive organic base fee growth, and higher securities lending revenue. BlackRock Inc (NYSE: BLK ) reported Q4 FY23 revenue growth of 7% Y/Y to $4.631 billion, marginally above the consensus of $4.627 billion. billion from $3.40

article thumbnail

Incyte Acquires Villaris Therapeutics, Deepening Portfolio For Immune-Mediated Dermatologic Diseases

Benzinga

Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in 2023. Under the terms of the. Full story available on Benzinga.com.

Beta 52
article thumbnail

Data Update 1 for 2025: The Draw (and Danger) of Data

Musings on Markets

Not surprisingly, the company listings are across the world, and I look at the breakdown of companies, by number and market cap, by geography: As you can see, the market cap of US companies at the start of 2025 accounted for roughly 49% of the market cap of global stocks, up from 44% at the start of 2024 and 42% at the start of 2023.

article thumbnail

Data Update 1 for 2023: Setting the table!

Musings on Markets

In January 2023, I ended up with 47,913 publicly traded firms in my sample , with the pie chart below providing a geographic breakdown. I did my updates in the last week (January 1- January 5, 2023), and used the most updated data that I could find on each company. Cost of Equity 1. PE & PEG 2. Standard deviation in stock price 2.